[Sublingual, Transdermal, Subcutaneous] |
Issues for Surgery |
For opioid dependence – risk of withdrawal, relapse and accidental overdose (if relapses) if omitted. Re-initiation would be physically painful as patient would need to withdraw from other opioids before buprenorphine could be restarted1. For Buvidal® only – risk of QT-interval prolongation if continued (see Interaction(s) with Common Anaesthetic Agents and Interaction(s) with other Common Medicines used in the Perioperative Period). |
Advice in the Perioperative period |
Transdermal patch should be left in situ; at doses up to 70microgram/hour it is unlikely to interfere with the use of full opioid agonists for acute pain management2. For Opioid Dependence (sublingual or subcutaneous buprenorphine) For patient taking sublingual buprenorphine >12mg daily for opioid dependence some sources would advise tapering the dose 2 to 3 days pre-operatively following discussion with Substance Misuse team1; however, a recently published clinical practice advisory indicates buprenorphine should be continued pre-operatively irrespective of the dose3 (see Further Information). Combination Product:
See Further Information regarding the use of buprenorphine for opioid dependence. Emergency Surgery Transdermal patch should be left in situ; at doses up to 70microgram/hour buprenorphine is unlikely to interfere with the use of full opioid agonists for acute pain management2, 4, 5. For Opioid Dependence Combination Product:
See Further Information regarding the use of buprenorphine for opioid dependence. Perioperative Considerations For Opioid Dependence Post-operative Advice For Pain Relief Where possible, patients should be discharged on their usual medication, but if strictly necessary, they may be discharged with a limited prescription of full opioid agonist in addition to their usual / a reduced dose of buprenorphine3. A clear management plan should be communicated to the GP to ensure this combination is not continued long-term (see Opioids monograph). Transdermal patches are available as 72-hourly, 96-hourly and 7-day formulations; prescribers must ensure that the correct preparation is prescribed7. For Opioid Dependence Whilst opioid analgesia is not contraindicated in substance misuse patients, alternative forms of analgesia should be considered where possible. Adjunct analgesia (e.g. Non-Steroidal Anti-inflammatory Drugs [NSAIDs], paracetamol, gabapentin / pregabalin) should be first-line for post-operative pain, where appropriate3. If inadequate analgesia persists additional immediate-release full agonist opioids (morphine or fentanyl3) should be prescribed for post-operative surgical pain but the patient’s usual dose of buprenorphine should be continued. If pain is still problematic consider reducing buprenorphine dose; in which case monitor patient for 24 hours if receiving reduced buprenorphine dose while prescribed a full opioid agonist3 (see Interaction(s) with Common Anaesthetic Agents). Where possible, patients should be discharged on their usual medication, but if strictly necessary, they may be discharged with a limited prescription of full opioid agonist in addition to their usual / a reduced dose of buprenorphine (discuss with the patient’s Substance Misuse Team as this may impact upon their usual prescription and require additional follow up in the community)3. |
Interaction(s) with Common Anaesthetic Agents |
(Consult British National Formulary for available drugs in each class) *Buprenorphine has mixed agonist and antagonist properties; adequate analgesia may be difficult to achieve when administering a full opioid agonist. The potential to overdose with a full agonist exists, especially when attempting to overcome buprenorphine partial agonist effects or when buprenorphine plasma levels are declining8, 9, 10. Anaesthetic agents that may be used in the perioperative period that are known to, or predicted to, prolong the QT-interval include11: -
The possibility of QT-interval prolongation with concomitant administration of Buvidal® and the above listed medications is only theoretical; however, it may be prudent to monitor ECG with concurrent use if risk factors for QT-interval prolongation also present (increasing age, female sex, cardiac disease, and some metabolic disturbances e.g. hypokalaemia). |
Interaction(s) with other Common Medicines used in the Perioperative Period |
Macrolide Antibiotics Whilst single surgical prophylactic doses should not pose a problem, continued post-operative treatment may require close monitoring and possibly buprenorphine dose reduction. QT-Interval Prolongation (Buvidal® only) (see also Interaction(s) with other Common Medicines used in the Perioperative Period) Anaesthetic agents that may be used in the perioperative period that are known to, or predicted to, prolong the QT-interval include11: -
The possibility of QT-interval prolongation with concomitant administration of Buvidal® and the above listed medications is only theoretical; however, it may be prudent to monitor ECG with concurrent use if risk factors for QT-interval prolongation also present (increasing age, female sex, cardiac disease, and some metabolic disturbances e.g. hypokalaemia). |
Further Information |
Rationale for Continuing Buprenorphine Pre-operatively Receptor binding studies show reduced but conserved availability of μ-opioid receptors in patients taking buprenorphine. Patients receiving 2mg daily have 59% of μ-opioid receptors available, this reduces to 20% at 16mg daily and 16% at 32mg. It has previously been proposed that tapering to a dose of 12mg daily will increase μ-opioid receptor availability; however, this was only recommended to start a few days prior to surgery to reduce the risk of relapse1. Moreover, a recently published clinical practice advisory advocates continuing buprenorphine pre-operatively, regardless of dose. They suggest the buprenorphine dose should only be reduced post-operatively if pain cannot be managed by addition of adjunct analgesia and a full opioid agonist3. Buprenorphine for Opioid Dependence Hospitals should have local arrangements to guide the supply of buprenorphine to patients during their inpatient stay and at discharge. |
References |
|